Pioneering cell-based treatment for melanoma offered at Siteman Cancer Center

Siteman Cancer Center, based at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, is one of the first centers nationwide to offer a newly approved cell-based immunotherapy that targets melanoma.

J&J discontinues mid-stage dengue study, citing deprioritization of communicable disease work

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 5, 2024

In ‘march-in’ rights, some see a tool to lower drug prices. Others see a threat to intellectual property

In the fall of 2020, Robert Sachs was prescribed a medication to treat prostate cancer that had metastasized into some of his bones. He welcomed

January 22, 2024

CYTIVA FDA IASO Bio IND for equecabtagene autoleucel

The IND clearance is for the autoimmune disease indications non-renal systemic lupus erythematosus and lupus nephritis. Credit: Sebastian Kaulitzki/Shutterstock. IASO Biotherapeutics has secured US Food

August 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.